• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 5. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride: A Comprehensive Overview

4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride (CAS No. 88164-54-9) is a specialized chemical compound that has garnered significant attention in the field of pharmaceutical research and development. This compound, characterized by its unique structural and functional properties, holds promise in various therapeutic applications, particularly in the realm of anticancer and antimicrobial treatments. The introduction will delve into the compound's chemical structure, synthesis methods, pharmacological significance, and recent advancements in its application.

The molecular structure of 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride consists of a quinoline core substituted with a hydrazino group at the 4-position and a trifluoromethyl group at the 7-position. This arrangement imparts distinct electronic and steric properties to the molecule, making it a versatile candidate for further chemical modifications and biological evaluations. The hydrochloride salt form enhances its solubility in aqueous solutions, facilitating its use in various experimental and clinical settings.

The synthesis of 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride involves a multi-step process that typically begins with the preparation of 7-trifluoromethylquinoline. This intermediate is then subjected to selective functionalization at the 4-position using hydrazine derivatives under controlled conditions. The final step involves salt formation with hydrochloric acid to stabilize the compound. Recent advancements in synthetic methodologies have improved the yield and purity of this compound, making it more accessible for research purposes.

In terms of pharmacological activity, 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride has demonstrated promising results in preclinical studies. Its quinoline scaffold is known to exhibit potent effects against various pathogens and abnormal cell lines. The hydrazino group contributes to its reactivity, allowing it to interact with biological targets such as enzymes and nucleic acids. Additionally, the trifluoromethyl group enhances lipophilicity, which can improve cellular uptake and bioavailability.

Recent research has highlighted the potential of 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride as an anticancer agent. Studies have shown that it can induce apoptosis in cancer cells by inhibiting key signaling pathways involved in cell proliferation and survival. The compound's ability to disrupt microtubule formation and DNA replication further underscores its efficacy against malignant tumors. These findings have prompted further investigation into its mechanisms of action and potential therapeutic applications.

Beyond its anticancer properties, 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride has shown promise in combating resistant bacterial infections. The quinoline moiety is well-documented for its antimicrobial activity, while the hydrazino group adds an additional layer of interaction with bacterial enzymes. Preliminary studies indicate that this compound can effectively inhibit the growth of Gram-positive and Gram-negative bacteria, including strains that are resistant to conventional antibiotics.

The development of novel drug candidates often involves optimizing existing molecules for improved efficacy and reduced toxicity. In this context, 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride serves as a valuable scaffold for structure-activity relationship (SAR) studies. By modifying specific functional groups or exploring different analogs, researchers can fine-tune its pharmacological profile to meet specific therapeutic needs. Such efforts are crucial for advancing drug discovery programs and bringing new treatments to patients.

The use of computational methods has also played a significant role in understanding the behavior of 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride. Molecular modeling techniques allow researchers to predict how the compound interacts with biological targets at the atomic level. These insights can guide experimental design and help identify potential lead compounds for further development. Additionally, computational toxicology has been employed to assess the safety profile of this compound, ensuring that it meets regulatory standards before moving into clinical trials.

The future prospects for 4-Hydrazino 7-Trifluoromethyl-quinoline Hydrochloride are promising, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academia and industry are essential for translating preclinical findings into clinical reality. As our understanding of disease mechanisms continues to evolve, compounds like this one will play a critical role in developing innovative treatments for a wide range of diseases.

• 324-75-4(7-(Trifluoromethyl)-6-quinolinamine)
• 243666-11-7(4-Amino-7-(trifluoromethyl)quinoline)
• 247113-89-9(4-Amino-6-(trifluoromethyl)quinoline)
• 872604-29-0(9H-Carbazol-3-amine, 7-(trifluoromethyl)-)
• 1447606-61-2(5-(trifluoromethyl)quinolin-7-amine)
• 57369-92-3(4-Hydrazinyl-8-(trifluoromethyl)quinoline)
• 872604-18-7(9H-Carbazol-2-amine, 6-(trifluoromethyl)-)
• 872604-14-3(9H-Carbazol-2-amine, 7-(trifluoromethyl)-)
• 321-71-1(7-(trifluoromethyl)quinolin-5-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)